Molecule 2 Medicine

molecule2medicine.com

Molecule 2 Medicine Limited (M2M) is a private, UK based, biotechnology and pharmaceutical consulting company assisting global clients with the discovery, development and commercialisation of new human therapeutics. M2M provides clients with the technical skills required to run efficient drug discovery and drug development programs, along with the financial and commercial acumen and “back office” support to help their businesses succeed. M2M ensures that the growth of each client’s science is matched by their corporate development by providing guidance in such areas as venture capital/private equity capital raisings and interactions and negotiations with Pharma partners. M2M assist in creating new biotech businesses, providing operational assistance from the formation stage and guiding the evolution of companies on the right trajectory as they strive to develop new human therapeutics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

BEREN AWARDED EXPEDITED ROADMAP FOR TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Beren Therapeutics | November 18, 2022

news image

Beren Therapeutics, P.B.C. a biotechnology company, announced that its novel lead asset, BRN-002, was awarded an Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway for the reversal of atherosclerosis in patients with Homozygous Familial Hypercholesterolemia. The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or seriously debilitating diseases. HoFH is a rare gene...

Read More

CELL AND GENE THERAPY

PULMATRIX ANNOUNCES PATIENT DOSING COMPLETED FOR ITS NOVEL INHALED THERAPY PUR3100 FOR ACUTE MIGRAINE

Pulmatrix, Inc. | September 27, 2022

news image

Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, to...

Read More

MEDICAL

BIOCINA ANNOUNCES OPENING OF NEW GMP PLASMID DNA MANUFACTURING SUITE

BioCina | June 14, 2022

news image

BioCina, a leading contract development and manufacturing organization (CDMO) today announced that the company has expanded its CDMO service offering to include the manufacture of plasmid DNA (pDNA) in a new dedicated GMP suite. The suite is equipped with up to 300 L single use fermentation capacity and suitably scaled downstream processing equipment. To complement GMP manufacturing, a broad range of analytical methods have been developed to support in-process, release and stability testing of p...

Read More

INDUSTRIAL IMPACT

SHOUTI INTRODUCES BASECAMP BIO AS A WHOLLY OWNED SUBSIDIARY TO EXPAND PIPELINE AND PARTNERSHIPS

ShouTi Inc | February 18, 2022

news image

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships. Basecamp Bio integrates unique insights, skills, technological know-how and experience to navigate the complex challenges of membrane protein structure-based drug discovery. Its mission is to prosecut...

Read More
news image

INDUSTRIAL IMPACT

BEREN AWARDED EXPEDITED ROADMAP FOR TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Beren Therapeutics | November 18, 2022

Beren Therapeutics, P.B.C. a biotechnology company, announced that its novel lead asset, BRN-002, was awarded an Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway for the reversal of atherosclerosis in patients with Homozygous Familial Hypercholesterolemia. The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or seriously debilitating diseases. HoFH is a rare gene...

Read More
news image

CELL AND GENE THERAPY

PULMATRIX ANNOUNCES PATIENT DOSING COMPLETED FOR ITS NOVEL INHALED THERAPY PUR3100 FOR ACUTE MIGRAINE

Pulmatrix, Inc. | September 27, 2022

Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, to...

Read More
news image

MEDICAL

BIOCINA ANNOUNCES OPENING OF NEW GMP PLASMID DNA MANUFACTURING SUITE

BioCina | June 14, 2022

BioCina, a leading contract development and manufacturing organization (CDMO) today announced that the company has expanded its CDMO service offering to include the manufacture of plasmid DNA (pDNA) in a new dedicated GMP suite. The suite is equipped with up to 300 L single use fermentation capacity and suitably scaled downstream processing equipment. To complement GMP manufacturing, a broad range of analytical methods have been developed to support in-process, release and stability testing of p...

Read More
news image

INDUSTRIAL IMPACT

SHOUTI INTRODUCES BASECAMP BIO AS A WHOLLY OWNED SUBSIDIARY TO EXPAND PIPELINE AND PARTNERSHIPS

ShouTi Inc | February 18, 2022

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships. Basecamp Bio integrates unique insights, skills, technological know-how and experience to navigate the complex challenges of membrane protein structure-based drug discovery. Its mission is to prosecut...

Read More